AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. Show more

Location: 150 West 4th Ave, Vancouver, BC, V5Y 1G6, Canada | Website: https://www.abcellera.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.724B

52 Wk Range

$1.89 - $6.41

Previous Close

$5.77

Open

$5.80

Volume

5,402,271

Day Range

$5.75 - $6.48

Enterprise Value

1.376B

Cash

553.1M

Avg Qtr Burn

-20.21M

Insider Ownership

22.94%

Institutional Own.

38.41%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.